Is DRUG INTERACTION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DRUG INTERACTION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DRUG INTERACTION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DRUG INTERACTION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DRUG INTERACTION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DRUG INTERACTION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DRUG INTERACTION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DRUG INTERACTION: 1
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DRUG INTERACTION is a reported side effect: 0.0300%

FDA reports of any drug causing DRUG INTERACTION : 50284
Average percentage for all medicated patients where DRUG INTERACTION is reported as a complication: 0.3152%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DRUG INTERACTION:

ASPIRIN (3975 patients)
SIMVASTATIN (3016 patients)
WARFARIN SODIUM (2875 patients)
OMEPRAZOLE (2503 patients)
FUROSEMIDE (2320 patients)
SEROQUEL (1748 patients)
LYRICA (1746 patients)
LEVOTHYROXINE SODIUM (1683 patients)
RAMIPRIL (1663 patients)
ACETAMINOPHEN (1551 patients)
ATENOLOL (1495 patients)
CLARITHROMYCIN (1440 patients)
CHANTIX (1404 patients)
LIPITOR (1399 patients)
ZOCOR (1386 patients)
PREDNISOLONE (1386 patients)
CITALOPRAM HYDROBROMIDE (1378 patients)
LORAZEPAM (1353 patients)
LASIX (1353 patients)
DIGOXIN (1326 patients)
ALLOPURINOL (1316 patients)
NEXIUM (1305 patients)
LISINOPRIL (1296 patients)
PLAVIX (1285 patients)
COUMADIN (1225 patients)
RISPERDAL (1144 patients)
METFORMIN HCL (1137 patients)
TRAMADOL HCL (1113 patients)
CYMBALTA (1080 patients)
DIAZEPAM (1047 patients)
METHOTREXATE (1044 patients)
AMLODIPINE (1032 patients)
CLOZAPINE (1019 patients)
FLUOXETINE (987 patients)
LAMICTAL (983 patients)
GABAPENTIN (927 patients)
RISPERIDONE (919 patients)
ZOLOFT (905 patients)
CLONAZEPAM (892 patients)
REMICADE (891 patients)
VALPROATE SODIUM (884 patients)
NEURONTIN (884 patients)
MIRTAZAPINE (883 patients)
FENTANYL (881 patients)
LANSOPRAZOLE (872 patients)
TEGRETOL (871 patients)
EFFEXOR (869 patients)
CARBAMAZEPINE (867 patients)
HYDROCHLOROTHIAZIDE (863 patients)
CORDARONE (855 patients)
PREDNISONE (852 patients)
FLUCONAZOLE (836 patients)
ZYPREXA (834 patients)
PREVISCAN (818 patients)
IBUPROFEN (815 patients)
ATORVASTATIN CALCIUM (814 patients)
ALDACTONE (812 patients)
AMIODARONE HCL (805 patients)
SPIRONOLACTONE (781 patients)
BISOPROLOL FUMARATE (768 patients)
LAMOTRIGINE (765 patients)
LITHIUM CARBONATE (764 patients)
XANAX (752 patients)
CYCLOSPORINE (740 patients)
ENALAPRIL MALEATE (732 patients)
NORVASC (730 patients)
CIPROFLOXACIN (712 patients)
CRESTOR (709 patients)
VALPROIC ACID (705 patients)
FOLIC ACID (702 patients)
SYNTHROID (682 patients)
TACROLIMUS (681 patients)
LEXAPRO (673 patients)
WARFARIN (669 patients)
MORPHINE (647 patients)
CLOZARIL (647 patients)
PHENYTOIN (647 patients)
PROPOFOL (639 patients)
METOPROLOL TARTRATE (637 patients)
OLANZAPINE (634 patients)
CLOPIDOGREL (618 patients)
ALPRAZOLAM (618 patients)
AMITRIPTYLINE HCL (618 patients)
PAROXETINE HCL (616 patients)
DEPAKENE (605 patients)
METOCLOPRAMIDE (601 patients)
POTASSIUM CHLORIDE (599 patients)
METHADONE HCL (586 patients)
CARVEDILOL (586 patients)
LANTUS (578 patients)
SINTROM (577 patients)
ABILIFY (562 patients)
CELEBREX (554 patients)
TORSEMIDE (550 patients)
ACETYLSALICYLIC ACID SRT (550 patients)
TRAZODONE HCL (548 patients)
ATORVASTATIN (536 patients)
INSULIN (524 patients)
BISOPROLOL (523 patients)
HALOPERIDOL (522 patients)
PROZAC (517 patients)
PARACETAMOL (508 patients)
PANTOPRAZOLE SODIUM (503 patients)
AMOXICILLIN (502 patients)
METFORMIN (500 patients)
VENLAFAXINE HCL (500 patients)
PAXIL (493 patients)
HALDOL (489 patients)
KEPPRA (488 patients)
OXYCODONE HCL (485 patients)
PANTOPRAZOLE (485 patients)
RITONAVIR (482 patients)
DEXAMETHASONE (479 patients)
ACETYLSALICYLIC ACID (474 patients)
ALBUTEROL (472 patients)
DURAGESIC-100 (469 patients)
AMLODIPINE BESYLATE (463 patients)
QUETIAPINE (455 patients)
PROGRAF (453 patients)
NITROGLYCERIN (452 patients)
ESCITALOPRAM (443 patients)
WELLBUTRIN (442 patients)
TOPIRAMATE (438 patients)
ARICEPT (437 patients)
METRONIDAZOLE (437 patients)
METOPROLOL (434 patients)
VERAPAMIL (433 patients)
METOPROLOL SUCCINATE (433 patients)
PRAVASTATIN (428 patients)
LEVOFLOXACIN (428 patients)
FOSAMAX (428 patients)
ALTACE (428 patients)
TOPAMAX (424 patients)
VOLTAREN (424 patients)
COLCHICINE (422 patients)
SERTRALINE HYDROCHLORIDE (414 patients)
ITRACONAZOLE (413 patients)
EFFEXOR XR (413 patients)
AMBIEN (412 patients)
KLONOPIN (408 patients)
DEPAKOTE (407 patients)
PREDNISONE TAB (406 patients)
NEORAL (406 patients)
RIFAMPICIN (404 patients)
NIFEDIPINE (403 patients)
PROPRANOLOL (402 patients)
ERYTHROMYCIN (400 patients)
OXYCONTIN (400 patients)
LAMIVUDINE (400 patients)
ISOSORBIDE MONONITRATE (396 patients)
DIOVAN (391 patients)
ZOLPIDEM (384 patients)
VIAGRA (383 patients)
DILANTIN (382 patients)
GLEEVEC (382 patients)
COZAAR (382 patients)
KALETRA (381 patients)
AZATHIOPRINE (380 patients)
GLUCOPHAGE (377 patients)
RANITIDINE (372 patients)
MORPHINE SULFATE (370 patients)
AZITHROMYCIN (367 patients)
TOPROL-XL (367 patients)
FENOFIBRATE (362 patients)
MYCOPHENOLATE MOFETIL (360 patients)
DILTIAZEM (351 patients)
MICONAZOLE (351 patients)
VENLAFAXINE (350 patients)
ALL OTHER THERAPEUTIC PRODUCTS (348 patients)
SPIRIVA (348 patients)
BACTRIM (344 patients)
DICLOFENAC SODIUM (341 patients)
QUETIAPINE FUMARATE (341 patients)
ZOPICLONE (338 patients)
VITAMIN D (335 patients)
PROTONIX (329 patients)
PRILOSEC (328 patients)
GLYBURIDE (328 patients)
PROVIGIL (320 patients)
CITALOPRAM (319 patients)
ALCOHOL (318 patients)
DOXAZOSIN MESYLATE (316 patients)
VANCOMYCIN (316 patients)
RHEUMATREX (316 patients)
ZOLPIDEM TARTRATE (315 patients)
ZETIA (313 patients)
LEPONEX (313 patients)
CYCLOPHOSPHAMIDE (311 patients)
TRILEPTAL (310 patients)
ATACAND (306 patients)
CELLCEPT (306 patients)
REGLAN (305 patients)
GEODON (304 patients)
HEPARIN (304 patients)
LITHIUM (304 patients)
STRATTERA (303 patients)
AMIODARONE (302 patients)
SINEMET (301 patients)
HUMIRA (300 patients)
VALSARTAN (300 patients)
ADVAIR DISKUS 100/50 (294 patients)
VIOXX (294 patients)
CALCIUM CARBONATE (292 patients)
PANTOZOL (292 patients)
VFEND (291 patients)
OXAZEPAM (290 patients)
VORICONAZOLE (289 patients)
OXCARBAZEPINE (287 patients)
TRUVADA (286 patients)
NORVIR (286 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DRUG INTERACTION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.